1 / 3

Women’s Health Initiative: Trial of Estrogen plus Progestin

Women’s Health Initiative: Trial of Estrogen plus Progestin. 16,608 women randomized Conjugated equine estrogens 0.625 mg/d + medroxyprogesterone acetate 2.5 mg/d vs. placebo Primary outcome: nonfatal MI or CHD death Primary adverse outcome: breast cancer

shing
Download Presentation

Women’s Health Initiative: Trial of Estrogen plus Progestin

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Women’s Health Initiative: Trial of Estrogen plus Progestin • 16,608 women randomized • Conjugated equine estrogens 0.625 mg/d + medroxyprogesterone acetate 2.5 mg/d vs. placebo • Primary outcome: nonfatal MI or CHD death • Primary adverse outcome: breast cancer • Stopped early (mean follow-up 5.2 years) because health risks exceeded benefits Writing Group for the WHI Investigators. JAMA 2002;288:321-333.

  2. Risks and Benefits of Estrogen/Progestin on Clinical Outcomes: Women’s Health Initiative *1st event: CHD; stroke; pulmonary embolism; breast, endometrial, or colorectal cancer; hip fracture, or death due to other causes Writing Group for the WHI Investigators. JAMA 2002;288:321-333.

  3. Absolute Excess Risks and Absolute Risk Reductions per 10,000 Person-Years: Women’s Health Initiative Writing Group for the WHI Investigators. JAMA 2002;288:321-333.

More Related